Abstract
Liver cancer is considered the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide. Currently, there is no specific and effective therapy for hepatocellular carcinoma. Therefore, developing novel diagnostic and therapeutic strategies against hepatocellular carcinoma is of paramount importance. Solute carrier family 6 member 8 (SLC6A8) encodes the solute carrier family 6-8 to transport creatine into cells in a Na\(^+\) and Cl\(^-\) dependent manner. SLC6A8 deficiency is characterized by intellectual disabilities, loss of speech, and behavioral abnormalities. Of concern, the association of SLC6A8 with hepatocellular carcinoma remains elusive. In this study, we revealed that SLC6A8 knockdown significantly induced apoptosis and suppressed the migration and invasion of Hep3B and Huh-7 cells. These findings depicted the vital role of SLC6A8 in the initiation and progression of human hepatocellular carcinoma.

Keywords
hepatocellular carcinoma cells, slc6a8, proliferation and apoptosis, migration and invasion

Abbreviations
CCDS, Cerebral creatine deficiency syndrome; DMEM, Dulbecco’s modified eagle medium; FBS, fetal bovine serum; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SLC6A8, Solute carrier family 6 member 8; MTT, 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide; TACE, hepatic artery chemoembolization; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; RNAi, RNA interference; RT-PCR, Reverse transcription polymerase chain reaction

Introduction
According to the Global Cancer Statistics in 2018, both new cancer cases and cancer-related deaths were 18.1 million and 9.6 million worldwide, respectively.\(^1\) However, liver cancer is considered the sixth commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide. Of concern, 841,000 new cases and 782,000 deaths are reported annually, hence seriously threatening the lives and health of people as well as accompanied by financial burden.\(^1,2\) Based on the global new cases reported annually, 50% are from China but not exceeding 350,000 people.\(^3\) Hepatocellular carcinoma (HCC) potentially advances into chronic liver disease following either hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and alcohol consumption or metabolic syndrome.\(^4\) Previous studies had determined HCC as a significant threat to the health and property safety of people. Besides, there is still a lack of mature and convincing theory on specific and precise cellular molecular mechanisms of the initiation and development of HCC.\(^5\) Decrypting the underlying molecular
were sourced from the Stem Cell Library of the Chinese
Cell Culture
Methods
Cell Culture
Human hepatocellular carcinoma Huh-7 and Hep3B cell lines were sourced from the Stem Cell Library of the Chinese

SLC6A8 Gene Knockdown in Huh-7 and Hep3B Cells
To silence SLC6A8, Huh-7 and Hep3B cells we transfected commercially synthesized lentiviral vectors harboring SLC6A8 siRNA. The lentiviral vectors containing siRNA sequences of NC, KD1 and KD2 (Table 1) were synthesized by Shanghai Genechem Co., Ltd. Thereafter, the cells were classified into Con (no lentivirus transfection), NC (cells transfected with NC lentivirus), KD1 (cells transfected with lentivirus containing KD1 sequence) and KD2 (cells transfected with lentivirus containing KD2 sequence) groups. Either LV-SLC6A8-siRNA or LV-NC-siRNA was transfected into Huh-7 and Hep3B cells at 60% confluence followed by immediate addition of 2 μg/mL of puromycin and removed from the medium at 72 h later. Then, the transfection efficiency was determined via quantitative real-time PCR (RT-PCR), western blot and immunofluorescence assay.

Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)
Total RNA from each sample was isolated using Trizol (no.15596026, Invitrogen) as per the manufacturer’s instructions. Total RNA concentration was determined using ND-2000 Spectrophotometer (Thermo Fisher Scientific, USA). Quantitative real-time PCR (q-PCR) was performed with the KAPA SYBR FAST qPCR Kit (Kapa Biosystems, USA) using a 7300 Real-Time PCR System (Applied Biosystems, Wal- tham, MA). Primer pairs of mRNAs used are listed in Table 2. RT-PCR data were analyzed using 2^(-⊿⊿CT) method.16

Western Blot
Following washing of treated cells with cold PBS, their proteins were extracted using radioimmunoprecipitation assay (RIPA) with a lysis buffer (P0013B, Beyotime Biotechnology, China) supplemented with protease inhibitor. The concentration of extracted protein was determined by BCA assay.17 Proteins were separated using 12% SDS-polyacrylamide gel electrophoresis before transferred to polyvinylidene fluoride (PVDF) membranes using a wet membrane apparatus and blocked for 1 h with PBS containing 5% skimmed milk powder.18 Details of primary antibodies used are in Table 3.

Table 1. Primer Sequence of Negative Control, KD1 and KD2 siRNA of SLC6A8.

| siRNA | Primer sequence |
|-------|-----------------|
| KD1 | ATTACCTGGTCAAGTCCCTTTA |
| KD2 | ATTACCTGGTCAAGTCCCTTTA |
| NC  | TCTCCGAACGTGCACGT |

Table 2. Primers Used for Real-Time PCR.

| Gene name | Sequence |
|-----------|----------|
| hSLC6A8-160-F | CATCTCCAAGGACGAGT |
| hSLC6A8-160-R | GATGAAGCCCTACACCTA |
| GAPDH-127F | CCAGGTGGTCTCCTCTGA |
| GAPDH-127R | GCTTACGCAAATCTGTTG |

Academy of Sciences. Huh-7 cells were maintained in Dulbec-co’s modified Eagle’s medium (DMEM, HyClone) whereas Hep3B cells in Eagle’s Minimum Essential Medium (MEM, HyClone) supplemented with 10% fetal bovine serum (FBS, Gibco).14,15

SLC6A8 expression significantly in hepatocellular carcinoma Huh-7 and Hep3B cells using the Gene Chip (Supplementary materials Figure 1). Besides, the SLC6A8 protein level was increased in the liver tissues of HCC patients which was correlated to the histological grade of HCC indicated in the TCGA database (Supplementary materials Figure 2). However, the role of increased SLC6A8 in the framework of hepatocellular carcinoma remains unclear.

The present study purposed to explore the function and regulation of SLC6A8 on the phenotype of hepatocellular carcinoma. Based on loss-of-function studies, we demonstrated for the first time that knockdown of SLC6A8 suppressed the migration and invasion of Huh-7 and Hep3B cells in vitro. Furthermore, SLC6A8 knockdown partially mediated biological functions in human hepatocellular carcinoma.

mechanisms of cell biology will shed light on the complex molecular and cellular pathways that mediate the initiation and progression of HCC. In addition, it will provide a potential treatment strategy against HCC.6

Solute carrier family 6 member 8 (SLC6A8) encodes the solute carrier family 6-8 to transport creatine into cells in a Na^+ and Cl^- dependent manner.7 Since creatine is a nitrogen-containing acid involved in energy balance, it plays a vital role in ATP homoeostasis for high-energy demanding tissues such as heart, brain and skeletal muscle.8 Creatine kinase converts creatine into an intracellular phosphocreatine, which serves as ATP storage.9 Cerebral creatine deficiency syndrome (CCDS) is characterized by intellectual disability and aphasia. However, SLC6A8 defects are the common types of CCDS and are responsible for 2% of the related intellectual disability.10 Therefore, deficiency of SLC6A8 in the brain will eventually lead to severe neurological diseases like epilepsy and mental retardation.11,12 Although intellectual disability is the most profound hallmark of SLC6A8 deficiency patients, the rate of behavioral abnormalities mainly consists of high attention deficit, hyperactivity and autistic features.13 Notably, the association of SLC6A8 deficiency with the intellectual disability and behavioral abnormalities were determined, but the role of SLC6A8 in the initiation and progression of cancer remains indistinct.

We previously revealed that hypoxia-induced SLC6A8 expression significantly in hepatocellular carcinoma Huh-7 and Hep3B cells using the Gene Chip (Supplementary materials Figure 1). Besides, the SLC6A8 protein level was increased in the liver tissues of HCC patients which was correlated to the histological grade of HCC indicated in the TCGA database (Supplementary materials Figure 2). However, the role of increased SLC6A8 in the framework of hepatocellular carcinoma remains unclear.

The present study purposed to explore the function and regulation of SLC6A8 on the phenotype of hepatocellular carcinoma. Based on loss-of-function studies, we demonstrated for the first time that knockdown of SLC6A8 suppressed the migration and invasion of Huh-7 and Hep3B cells in vitro. Furthermore, SLC6A8 knockdown partially mediated biological functions in human hepatocellular carcinoma.
Cell Viability Assay

Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. Both Huh-7 and Hep3B cells were transfected for 12 h and seeded in 96-well plates at a concentration of $5 \times 10^3$ cells per well in 200 μL complete medium. Thereafter, 20 μL MTT liquid (5 mg/mL, A600799-0005, Sangon Biotech, Shanghai, China) was added on each well for 4 h after culturing for 48 h. Subsequently, 150 mL DMSO was added into each well and oscillated at low-speed on a shaker for 10 min after discarding the supernatant. Absorbance values were determined at 490 nm using an automated microplate reader (Nanophtoometer P360, Germany) after culturing the cells for 1–6 days. The growth curve was plotted on OD (y-axis) against time (x-axis). Values at a wavelength of 490 nm were measured using an automated microplate reader.

Cell Apoptosis Test

Apoptotic changes in KD-SLC6A8 Huh-7 and Hep3B cells were evaluated using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining assay (11684817910, Roche) according to the manufactures instructions. The apoptotic index was determined from the TUNEL-positive cells counted at X 40 in random sections. A ratio of the numbers of positive to negative cells in each group was determined.

Cell Migration Assays

Cell migration assays were used to determine the motility of human hepatocellular carcinoma cells. Briefly, Huh-7 and Hep3B cells were diluted to $1 \times 10^5$ cells/well and seeded in 24-well culture plates. Thereafter, the cell monolayer was gently scratched with a sterile 200-μL pipette tip to generate a straight thin gap. The scratched cells were washed twice to remove the cell debris using PBS. Images of the scratch were obtained at 0, 24 and 48 h while the width of the cell gap was quantified using Image J software. The migration ratio was calculated as follows:

$$\text{Migration ratio} = \left( \frac{V_{T0} - V_{T1}}{V_{T0}} \right) \times 100\%.$$  

Cell Invasion Assays

Cell invasion ability was examined using Transwell assay with 24-well Transwell chambers (3413, Millipore, USA). A total of $1 \times 10^6$ cells was resuspended in serum-free medium and seeded to the inner chamber. The bottom chamber was incubated with 600 μL medium containing 20% FBS with 3 replicates for 24 h. Consequently, cells on the basolateral chamber were stained, photographed and counted in 6 random fields per group using a microscope (200X).

Statistical Analysis

Statistical analysis was conducted using the GraphPad Prism 5 (GraphPad Software, USA). Data was presented in mean ± standard deviation. p < 0.05 was considered statistically significant on a one-way ANOVA using SPASS 18.0 (SPASS, IL) followed by Duncan’s post hoc test.

Results

Construction of SLC6A8 Gene KnockDown (KD) in Human hepatocellular Carcinoma (Huh-7 and Hep3B) Cells

To explore the potential role of the SLC6A8 gene in human hepatocellular carcinoma, we genetically manipulated Huh-7 and Hep3B cells and developed cells with the SLC6A8 gene deleted (KD-SLC6A8). Based on the immunofluorescence assay, the transfection efficiency of LV-SLC6A8-siRNA in Hep3B and Huh-7 cells were analyzed by immunofluorescence assay.

incubated with 600 μL medium containing 20% FBS with 3 replicates for 24 h. Consequently, cells on the basolateral chamber were stained, photographed and counted in 6 random fields per group using a microscope (200X).

Statistical Analysis

Statistical analysis was conducted using the GraphPad Prism 5 (GraphPad Software, USA). Data was presented in mean ± standard deviation. p < 0.05 was considered statistically significant on a one-way ANOVA using SPASS 18.0 (SPASS, IL) followed by Duncan’s post hoc test.

Figure 1. The expression of SLC6A8 was silenced in Hep3B and Huh-7 cells. A. The transfection efficiency of LV-SLC6A8-siRNA in Hep3B and Huh-7 cells were analyzed by immunofluorescence assay. B. The expression of SLC6A8 in GNE-2 and Huh-7 cells was verified by real-time-PCR. Data are from 3 independent experiments shown as mean ± SD. *p < 0.05.
Absence of the SLC6A8 gene was observed at the mRNA level using RT-PCR in the KD- SLC6A8 Huh-7 and Hep3B cells (Figure 1B). The relative expression of SLC6A8 in Huh-7 cells was $1.0 + 0.10, 1.29 + 0.11, 0.23 + 0.10$ and $0.61 + 0.06$ in CON, NC, KD1 and KD2 group, respectively. However, the relative expression of SLC6A8 in Hep3B cells was $1.0 + 0.07, 1.36 + 0.05, 0.47 + 0.05$ and $0.75 + 0.12$ in CON, NC, KD1 and KD2 group, respectively. SLC6A8 level in the KD group was significantly less than in the NC group ($p < 0.05$). Interestingly, the knockdown efficiency of KD1 group was higher than the KD2 group for both Huh-7 and Hep3B cells. Besides, the absence of the SLC6A8 gene was observed at the protein level using Western blot assay (Figure 2A and B). The reduced expression of SLC6A8 led to the decline of the HiF1α expression (Figure 2A and B).

**Figure 2.** The absence of the SLC6A8 gene was observed at the protein level. A. The expression of SLC6A8 and HiF1α in Hep3B and Huh-7 cells were analyzed by Western blot. B. The ratios of SLC6A8/GAPDH and HiF1α/LaminB were determined by densitometry. Densitometry data are shown as mean ± SD. ($n = 3$, *p<0.05)

**SLC6A8 Knockdown Suppressed the Proliferation of Huh-7 and Hep3B Cells**

Based on MTT assay, the viability of KD-SLC6A8 Huh-7 and Hep3B cells were significantly decreased ($p < 0.05$) (Figure 3). No remarkable change in proliferation rate and cell viability in KD group compared to NC group when SLC6A8 was silenced for 2 days in Hep3B cells, while the proliferation rate and cell viability decreased significantly on 4th and 5th day after SLC6A8 was silenced (Figure 3A). The proliferation rate and cell viability were significantly reduced on the 2nd day following the SLC6A8 silencing in Huh-7 cells (Figure 2B). Results revealed that silencing SLC6A8 in Huh-7 and Hep3B cells suppressed Huh-7 and Hep3B cells proliferation.
SLC6A8 Silencing Induces Apoptosis of Huh-7 and Hep3B Cells

The apoptosis of KD-SLC6A8 Huh-7 and Hep3B cells were significantly increased as confirmed by TUNEL (Figure 4A and B). Dark brown stains in KD group cells indicated apoptosis, while the Con and NC cell displayed purple. Apoptotic cells are stained light gray by TUNEL. The results revealed that SLC6A8 silencing accelerated the apoptosis of Huh-7 and Hep3B cells.

SLC6A8 Knockdown Blocked the Migration of Huh-7 and Hep3B Cells

To determine the role of SLC6A8 in advancing human hepatocellular carcinoma, we detected the migration ability of SLC6A8-KD Huh-7 and Hep3B cells using the scratch test. By silencing SLC6A8, it blocked the migration of SLC6A8-KD Hep3B cells while KD1 had an immense inhibition effect than KD2 group (Figure 5A and B). However, silencing SLC6A8 had no significant inhibition effect on the migration of SLC6A8-KD Huh-7 cells (Figure 6A and B).

Knockdown of SLC6A8 Inhibited the Invasion of Huh-7 and Hep3B Cells

To determine whether SLC6A8 regulates the invasion of Huh-7 and Hep3B cells, Transwell assay was used to detect the invasion ability of SLC6A8-KD Hep3B and Huh-7 cells. We demonstrated that knockdown of SLC6A8 profoundly suppressed the invasion of both Hep3B and Huh-7 cells (Figure 7A and B).

Discussion

Liver cancer, as the common malignant tumor with poor prognosis, is the second most lethal cancer globally. Rates of both incidence and mortality of liver cancer are 2 to 3 times higher than that of woman among men in most world regions. Currently, the commonly used clinical treatment methods against hepatocellular carcinoma are surgical resection, radiotherapy, chemotherapy, hepatic artery chemoembolization (TACE) and comprehensive treatment. Due to the limited and nonspecific serum markers of late diagnosis and tumor-associated resistance, the therapeutic effect on invasive and metastatic cancer remains poor. However, clinical practice and basic research have shown that the effect of these treatments are not ideal and cause problems such as chemotherapy resistance, treatment on recurrence and metastasis. Therefore, there is an urgent need to find new and effective targets for early diagnosis, treatment and prognosis of tumors.

RNA interference (RNAi) is a novel and powerful gene silencing tool that has potential in treating cancer and other diseases. The initiation of RNAi depends on various small RNA, which play an important role in the degradation of messenger RNA. RNAi refers to the adoption of silent gene
expressions such as short hair clip RNA (shRNA), small interference RNA (siRNA), and tiny interference (miRNA). However, SLC6A8 also called CRT, was highly expressed in hepatocellular carcinoma tissues and encoded a member of the solute carrier 6 family that specifically transports creatine into cells.27 High expression of SLC6A8 has been revealed in creatine-demanding organs such as skeletal muscle and brain.28 Characteristically, SLC6A8 deficiency leads to the absence of brain creatine and intellectual disabilities, loss of speech, and behavioral abnormalities.29-31 Following the consistent of the clinical manifestations of patients with SLC6A8 mutations, SLC6A8 deficiency in mice causes cognitive ability deficits and reduces body weight.32 Low expression of SLC6A8 was detected in mucosal biopsy specimens of

Figure 4. SLC6A8 silencing induced cell apoptosis in Hep3B and Huh-7 cells. A. Cell apoptosis after transfection in Hep3B cells detected by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). B. Cell proliferation after transfection in Huh-7 cells detected by MTT. Data are from 3 independent experiments shown as mean ± SD. *p < 0.05.
patients with ulcerative colitis and inactive Crohn’s disease, hence attributed to the reduced barrier function observed in inflammatory bowel diseases patients. However, the association of SLC6A8 with hepatocellular carcinoma remains unclear. Besides using the loss-of-function studies, our study explores the function of SLC6A8 on human hepatocellular carcinoma cells.

Both the Hep3B and Huh-7 cells were used as surrogates for human hepatocellular carcinoma cells. Besides, Hep3B and Huh-7 cell lines were utilized to assess the drug metabolism and toxicity of the human liver despite being proposed as an in vitro model for human hepatocellular carcinoma cells. On the other hand, the role of SLC6A8 in human hepatocellular carcinoma cells was examined following the SLC6A8 gene

Figure 5. SLC6A8 silencing suppressed cell migration in Hep3B cells. A. Representative images showing the effects of SLC6A8-KD on the migration of Hep3B cells. B. Quantification of the migration rate in 3 separate experiments was shown. Data are shown as mean ± SD. (n = 3, *p < 0.05)
knockdown by transfecting lentivirus vectors harboring SLC6A8 siRNA, which is an efficient and highly specific approach for engineering eukaryotic genomes.\textsuperscript{36-38} In the knockdown cells, there was a significantly low expression of SLC6A8, thus confirming the efficiency of the partial removal of the gene. Due to the knockdown of SLC6A8 expression by siRNA, proliferation was suppressed, but apoptosis was significantly induced in Huh7 and Hep3B cells. Similar findings were observed when determining the role of SLC6A8 in fibroblasts on creatine deficiency syndrome patients.\textsuperscript{39} Furthermore, the \textit{in vitro} silencing of SLC6A8 suppressed the invasion and migration of both Huh7 and Hep3B cells, indicating that SLC6A8 may be a potential tumor promoter in human hepatocellular carcinoma. Therefore, silencing of the SLC6A8 gene represents a promising novel therapeutic target for the treatment of hepatocellular carcinoma.

Figure 6. SLC6A8 silencing suppressed cell migration in Huh-7 cells. A. Representative images showing the effects of SLC6A8-KD on the migration of Huh-7 cells. B. Quantification of the migration rate in 3 separate experiments was shown. Data are shown as mean $\pm$ SD. ($n = 3$, *$p < 0.05$)
Conclusion
In summary, the present study showed knockdown of the SLC6A8 gene induces apoptosis and suppresses the migration and invasion of Hep3B and Huh-7 cells. These findings indicate that SLC6A8 is a promising therapeutic target for HCC.

Authors’ Note
Our study did not require ethical board approval because it did not contain human or animal trials.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the Guangxi Medical and Health Appropriate Technology Development and Application Project (S201653).

Figure 7. SLC6A8 Knockdown blocked the invasion of human hepatocellular carcinoma cells. A. Evaluation of invasion abilities of Huh-7 cells by Transwell invasion assay. B. Evaluation of invasion abilities of Hep3B cells by Transwell invasion assay. Representative images are shown (magnification ×200). Results are expressed as means ± SD. (n = 3, *p < 0.05)
ORCID iD
Jian Pu https://orcid.org/0000-0002-5091-8528

Supplemental Material
Supplemental material for this article is available online.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9848):2095-2128.
3. Tanaka M, Katayama F, Kato H, et al. Hepatitis b and c virus infection and hepatocellular carcinoma in china: a review of epidemiology and control measures. J Epidemiol. 2011;21(6):401-416.
4. Hemming AW, Berumen J, Mekeel K. Hepatitis b and hepatocellular carcinoma. Clin Liver Dis. 2016;20(4):703-720.
5. Motamedian E, Taheri E, Bagheri F. Proliferation inhibition of cisplatin-resistant ovarian cancer cells using drugs screened by integrating a metabolic model and transcriptomic data. Cell Pro lif. 2017;50(6):e12370.
6. Ronot M, Bouattour M, Wassermann J, et al. Alternative response criteria (choi, european association for the study of the liver, and modified response evaluation criteria in solid tumors [recist]) versus recist 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19(4):394-402.
7. Leuzzi V, Mastrangelo M, Battini R, Cioni G. Inborn errors of creatine metabolism and epilepsy. Epilepsia. 2013;54(2):217-227.
8. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem. 1994;133-134:51-66.
9. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem. 1998;184(1-2):427-437.
10. Van De Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, et al. Phenotype and genotype in 101 males with x-linked creatine transporter deficiency. J Med Genet. 2013;50(7):463-472.
11. Rosenberg EH, Almeida LS, Kleefstra T, et al. High prevalence of slc6a8 deficiency in X-linked mental retardation. Am J Hum Genet. 2004;75(1):97-105.
12. Salomonos GS, Van Dooren SJ, Verhoeven NM, et al. X-linked creatine transporter defect: an overview. J Inherit Metab Dis. 2003;26(2-3):309-318.
13. Van De Kamp JM, Mancini GM, Salomonos GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. J Inherit Metab Dis. 2014;37(5):715-733.
14. Barroso E, Rodriguez-Rodriguez R, Zarei M, et al. Sirt3 deficiency exacerbates fatty liver by attenuating the hif1alpha-lipin 1 pathway and increasing cd36 through nrf2. Cell Commun Signal. 2020;18(1):147.
15. Chan JK, Wai-Hung Ho D, Kam CS, et al. Rsk2-inactivating mutations potentiate mapk signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol. 2020;S0168-8272(20)33610-2.
16. Wei Y, Lu C, Zhou P, et al. EIF4A3-induced circular RNA ASAPI1(circASAPI1) promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1/2 signaling. Neuro Oncol. 2020;noaa214.
17. Gaspar LS, Santana MM, Henquies C, et al. Simple and fast sec-based protocol to isolate human plasma-derived extracellular vesicles for transcriptional research. Mol Ther Methods Clin Dev. 2020;18:723-737.
18. Chen Y, Wang J, Xu D, et al. M(6)a mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2020:1-19.
19. Wanderley DMS, Melo DF, Silva LM, et al. Biocompatibility and mechanical properties evaluation of chitosan films containing an n-acylhydrazonic derivative. Eur J Pharm Sci. 2020;155:105547.
20. Shankygar Khan SI, Malhotra RK, et al. The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-gamma in a murine model of myocardial infarction. Arch Biochem Biophys. 2020;694:108572.
21. Ji T, Zhang Y, Wang Z, Hou Z, Gao X, Zhang X. Foxd3-as1 suppresses the progression of non-small cell lung cancer by regulating MIR-150/SRCIN1axis. Cancer Biomark, 2020;29(3):417-427.
22. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
23. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339-348.
24. Cheng H, Sun G, Chen H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9(8):1536-1545.
25. Guo W, Chen W, Yu W, Huang W, Deng W. Small interfering RNA-based molecular therapy of cancers. Chin J Cancer. 2013;32(9):488-493.
26. Lion-Francois L, Cheillan D, Pitelet G, et al. High frequency of CDH1 and promotes breast cancer cell migration and invasion. Biochem J. 2020;477(19):3803-3818.
27. Gaspar LS, Santana MM, Henquies C, et al. Simple and fast sec-based protocol to isolate human plasma-derived extracellular vesicles for transcriptional research. Mol Ther Methods Clin Dev. 2020;18:723-737.
28. Ronot M, Bouattour M, Wassermann J, et al. Alternative response criteria (choi, european association for the study of the liver, and modified response evaluation criteria in solid tumors [recist]) versus recist 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19(4):394-402.
29. Leuzzi V, Mastrangelo M, Battini R, Cioni G. Inborn errors of creatine metabolism and epilepsy. Epilepsia. 2013;54(2):217-227.
30. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem. 1994;133-134:51-66.
31. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem. 1998;184(1-2):427-437.
32. Van De Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, et al. Phenotype and genotype in 101 males with x-linked creatine transporter deficiency. J Med Genet. 2013;50(7):463-472.
33. Rosenberg EH, Almeida LS, Kleefstra T, et al. High prevalence of slc6a8 deficiency in X-linked mental retardation. Am J Hum Genet. 2004;75(1):97-105.
34. Salomonos GS, Van Dooren SJ, Verhoeven NM, et al. X-linked creatine transporter defect: an overview. J Inherit Metab Dis. 2003;26(2-3):309-318.
35. Van De Kamp JM, Mancini GM, Salomonos GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. J Inherit Metab Dis. 2014;37(5):715-733.
31. Fons C, Sempere A, Arias A, et al. Arginine supplementation in four patients with x-linked creatine transporter defect. J Inherit Metab Dis. 2008;31(6):724-728.

32. Skelton MR, Schaefer TL, Graham DL, et al. Creatine transporter (CRT; slc6a8) knockout mice as a model of human crt deficiency. PLoS One. 2011;6(1):e16187.

33. Hall CHT, Lee JS, Murphy EM, et al. Creatine transporter, reduced in colon tissues from patients with inflammatory bowel diseases, regulates energy balance in intestinal epithelial cells, epithelial integrity, and barrier function. Gastroenterology. 2020;159(3):984-998.e1.

34. Meex SJ, Andreo U, Sparks JD, Fisher EA. Huh-7 or hepg2 cells: which is the better model for studying human apolipoprotein-b100 assembly and secretion? J Lipid Res. 2011;52(1):152-158.

35. Manov I, Hirsh M, Iancu TC. Acetaminophen hepatotoxicity and mechanisms of its protection by n-acetylcysteine: a study of Hep3B cells. Exp Toxicol Pathol. 2002;53(6):489-500.

36. Goncalves MA, Janssen JM, Holkers M, de Vries AA. Rapid and sensitive lentivirus vector-based conditional gene expression assay to monitor and quantify cell fusion activity. PLoS One. 2010;5(6):e10954.

37. Neshati Z, Liu J, Zhou G, Schalij MJ, de Vries AA. Development of a lentivirus vector-based assay for non-destructive monitoring of cell fusion activity. PLoS One. 2014;9(7):e102433.

38. Li F, Mahato RI. RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev. 2011;63(1-2):47-68.

39. Alcaide P, Merinero B, Ruiz-Sala P, et al. Defining the pathogenicity of creatine deficiency syndrome. Hum Mutat. 2011;32(3):282-291.